Loading...
•
Dec 31, 2021
EyePoint Pharmaceuticals Q4 2021 Earnings Report
EyePoint Pharmaceuticals reported mixed Q4 2021 results, with increased revenue offset by higher operating expenses and a net loss.
Key Takeaways
EyePoint Pharmaceuticals reported Q4 2021 financial results, featuring a rise in total net revenue to $11.5 million compared to $7.1 million in Q4 2020. Net product revenue increased to $11.2 million from $6.7 million year-over-year, driven by record customer demand for YUTIQ and DEXYCU. However, operating expenses also increased, leading to a net loss of $19.4 million, or ($0.59) per share, compared to a net loss of $15.5 million, or ($1.07) per share, in the prior year period. The company's cash and investments totaled $211.6 million as of December 31, 2021.
Total net revenue increased to $11.5 million in Q4 2021, compared to $7.1 million in Q4 2020.
Net product revenue for Q4 2021 was $11.2 million, up from $6.7 million in Q4 2020.
Operating expenses rose to $29.6 million in Q4 2021, compared to $19.9 million in the prior year period.
Net loss for Q4 2021 was $19.4 million, or ($0.59) per share, compared to a net loss of $15.5 million, or ($1.07) per share, in Q4 2020.
Revenue by Segment
Forward Guidance
EyePoint Pharmaceuticals expects that its cash on hand as of December 31, 2021, along with expected net cash inflows from product sales, will be sufficient to fund its current and planned operations into the second half of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...